The Irritable Bowel Syndrome Treatment Market is still largely underdeveloped, and pharmaceutical companies have a lot of potential to meet various unmet needs in this therapy area. Clinical trials are currently being conducted on a few promising products, which could speed up growth even more. Over the projection period, product sales of Irritable Bowel Syndrome Treatment Market are anticipated to increase significantly, primarily as a result of rising prevalence and the introduction of novel medications for the treatment of constipation-predominant irritable bowel syndrome (IBS).
One of the most prevalent functional gastrointestinal illnesses, irritable bowel syndrome is thought to affect between 10-15% of people worldwide. IBS is thought to impact between 25 and 45 million people in the United States, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a research organisation. IBS sufferers tend to be female in two out of three cases, and the majority are under 50.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/03/the-global-irritable-bowel-syndrome.html
